Skip to main content

Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.

GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results.

Division: 
Citation: 

Grimberg, Dominic C., Ankeet Shah, and Brant A. Inman. “Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.” Eur Urol Focus 6, no. 4 (July 15, 2020): 620–22. https://doi.org/10.1016/j.euf.2019.09.006.

Published Date: 
Wednesday, July 15, 2020
Published In: 
European Urology Focus
PMID: 
31561993